0
Iterum Therapeutics plc Banner Image

Iterum Therapeutics plc has reached its limit for free report views

Work for Iterum Therapeutics plc? Upgrade Your Profile and unlock all your annual reports.

Iterum Therapeutics plc

  • Ticker ITRM
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Iterum Therapeutics plc Logo Image
  • 11-50 Employees
  • Based in Dublin, Ireland
Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infectiveMore compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Iterum Therapeutics plc

Most Recent Annual Report

Iterum Therapeutics plc MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Iterum Therapeutics plc has reached its limit for free report views.